

D2d Enrollment ID: 4 4 4 4 4 4Audit Date date: 10 / 31 / 2018Participant Name: Mr. D2d Study**D2D Additional Data Collection Record Audit Checklist***This form should be completed for every participant randomized in the D2d study.***Concomitant Medication:** The participant source **Concomitant Medication list** should be reviewed in their entirety from the time of the screening visit to the participant's final study visit.

Has the participant taken any of the following medications regularly for a chronic condition at baseline and during participation in D2d? If yes, enter in the EDC Concomitant Medication Form		
Medication Class or Type Generic name (brand names or also known as)	Notes	Initials/ date
Thyroid Replacement Medication levothyroxine (Levoxyl, Synthroid, L-Thyroxine)	none	PRS 10/31/018
Anticoagulants/Antiplatelet Medications aspirin (ASA, baby aspirin, Ecotrin) clopidogrel (Plavix) ticlopidine (Ticlid) warfarin (Coumadin) ✓ rivaroxaban (Xarelto) dabigatran (Pradaxa) apixaban (Eliquis) edoxaban (Savaysa) enoxaparin (Lovenox) ticagrelor (Brilinta) prasugrel (Effient) dipyridamole/aspirin (Aggrenox) eptifibatide (Integrilin)	On warfarin since 8/1/2012- added to con-med list eCRF	10/31/018 PRS
Lipid Modifying Medications atorvastatin (Lipitor) pravastatin (Pravachol) Simvastatin (Zocor) ✓ pitavastatin (Livalo, Zypitamag) cerivastatin (Baycol) fluvastatin (Lescol, Lescol XL) lovastatin (Altoprev) rosuvastatin (Crestor) Ezetimibe (Zetia) Fenofibrate (Antara, Fenofibric acid, TriCor, Trilipix, Triglide, Lipofen Fenoglide) Colestipol (Colestid) Cholestyramine/sucrose (Questran) Colesevelam (Welchol) Alirocumab (Praluent) Evolocumab (Repatha) Icosapent ethyl (Vascepa)	On Zocor, already in con-med eCRF	PRS 10/31/018
Beta-blocker Medications acebutolol atenolol (Tenormin, Tenoretic*) carvedilol (Coreg) bisoprolol (Zebeta) labetalol (Trandate) metoprolol (Lopressor, Toprol XL) nadolol (Corgard) nebivolol (Bystolic, Byvalson*) propranolol (Inderal, Inderal LA)	none	PRS 10/31/018